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Abstract: Type 1 diabetes (T1D) is an autoimmune disorder with a strong inflammatory component. Autoreactive cells 
specifically target insulin-producing β-cells, which leads to loss of glucose homeostasis. T1D remains incurable and versatile; 
potentially beneficial therapeutics are being tested worldwide. Possible candidates for the treatment of autoimmune diabetes 
are plants and their extracts since they are rich in biophenols, substances that act as secondary metabolites, and have veri-
fied antioxidant and antiinflammatory effects. Salvianolic acid B (SalB) is a biophenol and one of the major constituents of 
Origanum vulgare ssp. hirtum (Greek oregano) extracts which in our previous studies was shown to exhibit an antidiabetic 
effect in mice. The aim of the present study was to determine whether SalB is responsible for the observed effects of Greek 
oregano extracts. SalB was applied in vitro to macrophages and lymphocytes isolated from C57BL/6 mice, as well as in vivo 
in the model of T1D induced by multiple low doses (MLD) of streptozotocin (STZ). SalB did not affect the viability of cells, 
but it significantly decreased secretion of nitric oxide (NO) and TNF in lipopolysaccharide (LPS)-stimulated macrophages, 
as well as the secretion of IFN-γ in concanavalin A (ConA)-stimulated lymphocytes. However, when applied in vivo, SalB 
at a dose of 2.5 mg/kg b.w., applied for 10 consecutive days, failed to protect mice from diabetes development. In conclu-
sion, SalB exerts immunomodulatory effects in vitro, but is not effective in prevention of T1D in vivo. It probably requires 
cooperation with some other substances for the maximum efficacy exhibited by oregano extracts.
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INTRODUCTION
Type 1 diabetes (T1D) is an autoimmune disorder where 
autoreactive immune cells specifically target insulin-pro-
ducing pancreatic β-cells [1]. Destruction of β-cells leads 
to impaired insulin secretion and ultimately to a loss of 
glucose homeostasis [2]. Combined genetic and envi-
ronmental factors lead to the immune response against 
β-cells [3]. The autoimmune response directs autoreac-
tive immune cells towards pancreatic islets and insulitis 
occurs [4]. Macrophages and autoreactive T lymphocytes 
make up most of the immune infiltrate [5], and their 
effector molecules, such as pro-inflammatory cytokines 
and nitric oxide, lead to the creation of a pro-inflam-
matory milieu, which is detrimental for β-beta cells [1]. 
While specific subsets of T helper (CD4+) cells, such as 
IFN-γ-producing Th1 cells and IL-17-producing Th17 
subsets, lead to T1D progression, IL-4-producing Th2 
cells and IL-2-producing Treg cells have an antiinflam-
matory role and can prevent T1D development [5-8].
T1D incidence is about 3% and is rapidly rising 
[9]. Currently, T1D is treated with daily insulin ad-
ministration [1] and constant efforts are being made 
in the search for novel therapeutic strategies to treat 
T1D. Plants and their extracts are becoming increas-
ingly interesting candidates for novel treatments of 
various ailments, including autoimmune diseases. 
This is mainly because plants are rich in biophenols 
and are considered to be less toxic and have fewer 
side effects than synthetic drugs. Biophenols are sub-
stances abundantly found in plants where they act as 
secondary metabolites [10]. A number of studies has 
linked intake of biophenols through diet with benefi-
cial effects in chronic diseases [11]. In our previous 
studies, we showed the antidiabetic effects of metha-
nolic and ethyl-acetate oregano extracts (Origanum 
vulgare ssp. hirtum) on the multiple low doses of 
streptozotocin (MLDS) experimental model of T1D 
[12,13]. Both substances are rich in salvianolic acid B 
(SalB), a water-soluble polyphenolic compound that 
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possesses anti-oxidant and anti-inflammatory effects 
[14]. The aim of this study was to investigate whether 
SalB is the substance responsible for the antidiabetic 
effects of methanolic and ethyl-acetate extracts of 
Origanum vulgare ssp. hirtum.
MATERIALS AND METHODS
Salvianolic acid B
Salvianolic acid B was a commercial sample obtained 
from Fluka (Buchs, Germany).
Animals
Male C57BL/6 mice, 8-12-weeks old were housed 
in the animal facility of the Institute for Biological 
Research. Their use and all experimental procedures 
were approved by the Ethics Committee of the in-
stitute (App. No. 01-07/15), which is in accordance 
with Directive 2010/63/EU. The mice were kept under 
standard conditions at a 12 h light/dark cycle with 
free access to a standard pelleted diet and tap water.
Cell preparation and culture
In vitro analysis was performed on male C57BL/6 
mice. To obtain cervical lymph node cells (CLNC), 
organs were mechanically disrupted by gentle teas-
ing through a cell strainer (BD Bioscience, Bedford, 
USA), and the cells were collected by centrifugation. 
Peritoneal cells (PC) were collected by washing the 
peritoneal cavity of mice with cold PBS. Samples of 
conditioned medium, used for in vitro detection of 
cytokines and NO, were obtained by seeding the cells 
(5×106 CLNC mL-1 well-1, or 1×106 PC mL-1 well-1) 
for 24 h (PC) and 48 h (CLNC) in 24-well culture 
plates (Sarstedt, Nümbrecht, Germany) in RPMI-1640 
medium (with 25 mmol/L HEPES, 2 mmol/L L-glu-
tamine) supplemented with 10% FCS (PAA Chemi-
cals, Pasching, Austria), penicillin/streptomycin 
(Sigma Aldrich, St. Louis, MO, USA), and 5 µmol/L 
β-mercaptoethanol at 37°C in a 5% CO2 incubator. 
Cells were cultured in the presence of mitogen activa-
tors ConA (1 µg/mL, Sigma Aldrich; CLNC) and LPS 
(5 ng/mL, Sigma Aldrich; PC).
Multiple low-dose streptozotocin-induced diabetes 
Immunoinflammatory T1D was induced in male 
8-12-week-old C57BL/6 mice with multiple low dos-
es of STZ (MLDS, 40 mg kg-1 day-1, intraperitoneally 
(i.p.) for five consecutive days, Sigma Aldrich). Each 
experimental group comprised 7 animals. Salvianolic 
acid B was administered i.p. for 10 consecutive days 
(2.5 mg kg-1 day-1), starting from the day of diabetes 
induction (prophylactic regimen). Mice were moni-
tored for diabetes by weekly measurement of blood 
glucose levels using a glucometer (Sensimac, IMA-
CO GmbH, Lüdersdorf, Germany). Clinical diabetes 
was defined by hyperglycemia in non-fasted animals 
(blood glucose>10 mmol/l).
Measurement of cytokine levels
Concentrations of cytokines in cell culture super-
natants were determined by a sandwich ELISA us-
ing MaxiSorp plates (Nunck, Rochild, Denmark) 
and anti-mouse-paired antibodies according to the 
manufacturer’s instructions. Samples were analyzed 
in duplicate for murine IL-17, IL-1β, TNF (BD Biosci-
ences), IFN-γ (eBioscience) and IL-4 (R&D Systems). 
Absorbance was measured by a LKB 5060-006 micro-
plate reader (LKB Instruments, Vienna, Austria) at 
450 and 570 nm.
Determination of nitrite levels
Nitrite accumulation, an indicator of NO production, 
was measured in cell culture supernatants using the 
Griess reagent [15]. Absorbance was measured by a mi-
croplate reader (LKB Instruments) at 540 and 650 nm.
Cell viability assay
Cell viability was determined by 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT) assay [16]. In brief, the cells were treated with 
0.5 mg/mL MTT solution for 30 min. In viable cells, 
tetrazolium salts were reduced to formazan crystals 
in the process of cell respiration. Purple formazan was 
then dissolved in dimethyl sulfoxide (DMSO) and the 
absorbance was measured in a LKB microplate reader 
at 540 and 670 nm.
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Statistical analysis
Data are presented as means±SD. Statistical analy-
sis was performed using Statistica 6.0 (StatSoft Inc., 
Tulsa, Okla., U.S.A.) software. Comparisons between 
the groups were performed by one-way ANOVA, fol-
lowed by Student-Newman-Keuls post hoc test and 
finally Student’s t-test or Mann-Whitney U-test, where 
appropriate. Analysis of diabetes incidence was per-
formed by the χ2 test. A p-value less than 0.05 was 
considered to be statistically significant.
RESULTS
The effect of SalB on peritoneal cells in vitro
To evaluate the potential influence of SalB on immune 
cells in vitro, PC rich in macrophages isolated from 
C57BL/6 mice and stimulated with LPS were treated 
with SalB at a concentration of 50 µg/mL. While SalB 
had no effect on the viability of peritoneal cells (Fig. 
1A), it significantly reduced their pro-inflammatory 
potential, judging by the reduced levels of NO (Fig. 1B) 
and reduced secretion of the pro-inflammatory cyto-
kine TNF (Fig. 1C). The concentration of SalB for in 
vitro experiments was determined on the basis of our 
previous work with Greek oregano extracts [12,13].
The effect of SalB on lymphocytes in vitro
While macrophages are the first cells to enter pan-
creatic islets, lymphocytes are the key players in T1D 
pathogenesis [5]. We therefore assessed the effect of 
SalB on lymphocytes. SalB (50 µg/mL) showed no cy-
totoxic effect on lymphocytes stimulated with ConA, 
judging by the viability assay (Fig. 2A). The effector 
function of lymphocytes was determined by measur-
ing the secretion of pro- and anti-inflammatory cyto-
kines (Fig. 2B). While SalB had no effect on the secre-
tion of anti-inflammatory IL-4 and pro-inflammatory 
IL-17, it significantly reduced the secretion of the pro-
inflammatory cytokine IFN-γ (Fig. 2B) and thereby 
lowered their total pro-inflammatory potential.
SalB does not prevent T1D development in vivo
To investigate the ability of SalB to prevent T1D de-
velopment in vivo, MLDS-challenged C57BL/6 mice 
were treated with SalB (i.p.) at a dose of 2.5 mg/kg 
b.w. in a prophylactic regime, every day for ten days. 
The dose of SalB for in vivo experiments was deter-
mined on the basis of our previous work with Greek 
Fig. 1. In vitro effect of SalB on macrophage viability and function. PC isolated from C57BL/6 mice were stimulated in vitro by LPS (5 
ng/mL) in the presence or absence of SalB (50 µg/mL). PC viability (A), secretion of NO (B) and cytokines (C) were measured after 24 
h of incubation. Results are presented as the means±SD. *P<0.05 refers to LPS+SalB-treated vs. LPS-treated PC.
Fig. 2. In vitro effect of SalB on lymphocyte function and viabil-
ity. Lymphocytes isolated from cervical lymph nodes of C57BL/6 
mice were stimulated in vitro with ConA (1 μg/mL) in the pres-
ence or absence of SalB (50 µg/mL). Lymphocyte viability (A) and 
secretion of cytokines (B) were measured after 48 h of incuba-
tion. Results are presented as the means±SD. *P<0.05 refers to 
ConA+SalB-treated vs. ConA-treated lymphocytes.
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oregano extracts [12,13]. Our results showed that SalB 
did not prevent T1D development (Fig. 3A), in fact 
the incidence of T1D was higher throughout the en-
tire experiment, although not statistically significant, 
than in the MLDS group (Fig. 3A). Additionally, the 
treatment with SalB showed no visible side effects on 
mice in terms of body weight gain (Fig 3B), behavior 
and general appearance (data not shown).
DISCUSSION
In this study, we present evidence that polyphenol 
SalB exerts an anti-inflammatory effect on both mac-
rophages and lymphocytes in vitro, but that it was un-
able to alter the autoimmune response in vivo and thus 
prevent T1D pathogenesis in C57BL/6 mice.
In our previous studies, we showed the antidiabetic 
effects of the methanolic and ethyl-acetate extracts of 
Origanum vulgare ssp. hirtum in an MLDS model of 
T1D [12,13]. However, search for the active component 
of these extracts was less successful, since neither rosma-
rinic acid nor carvacrol (constituents of these extracts) 
prevented the development of T1D [12,13, respectively]. 
SalB is another compound present in oregano extracts at 
a high concentration. It is frequently found in potentially 
immunomodulatory substances that are active in vitro, 
however, its effects do not appear to be translatable to 
an in vivo system [17]. In the present research, the in 
vitro anti-inflammatory potential of SalB was mediated 
by a reduction of TNF from macrophages, which is in 
accordance with the study of Sun et al. (2016), who also 
showed that SalB downregulated TNF secretion [18]. 
Macrophages also downregulated their NO produc-
tion after SalB treatment. Evidence from the literature 
describes the inhibitory effect of a similar compound, 
salvianolic acid A, on macrophage-derived NO [19]. 
However, SalB displayed an opposite effect in vivo in 
the model of rat hepatitis, where macrophages expressed 
higher levels of inducible NO synthase, the enzyme cru-
cial for induced NO synthesis [20].
SalB also exerted its in vitro immunomodulatory 
effect through the inhibition of lymphocyte-derived 
IFN-γ that is produced by Th1 and cytotoxic CD8+ 
(and to a smaller extent by NK cells). The effect of 
SalB on lymphocytes has been poorly studied and 
there are only data from one in vivo study where SalB 
inhibited Th1 activity during experimental autoim-
mune encephalomyelitis (EAE), a model of multiple 
sclerosis in rats [21].
Despite the obvious anti-inflammatory effect of 
SalB in vitro, a prophylactic treatment of MLDS-chal-
lenged mice with SalB failed to protect the mice from 
T1D development. In contrast, one study claims that 
SalB is antidiabetic in vivo, since it prevented the devel-
opment of hyperglycemia and subsequently increased 
insulin levels in Wistar rats [22]. However, there are 
several major differences that could be responsible 
for the different outcomes: the authors used outbred 
rats in the animal model, the doses of SalB were much 
higher (20 and 40 mg/kg b.w.), and were applied con-
tinuously for 3 weeks. Cells that contribute the most 
in the creation of an inflammatory milieu in T1D are 
T helper cells (Th1 and Th17), cytotoxic CD8+ lym-
phocytes [6,23] and inflammatory macrophages [24]. 
Since SalB suppressed the IFN-γ-producing popula-
Fig. 3. In vivo effect on SalB on T1D. T1D was induced in male 
C57BL/6 mice by the administration of STZ (40 mg/kg b.w., i.p.) 
for five consecutive days. One group of animals was simultaneous-
ly treated with SalB (2.5 mg/kg b.w., i.p) for 10 consecutive days 
(prophylactic treatment). The animals were monitored weekly 
for changes in blood glucose levels (A) and body weight (B). The 
results from one representative result out of three experiments 
with similar results are presented as the means±SD (n=7 mice per 
group). Statistical comparisons were made by one-way ANOVA 
followed by Student-Newman-Keuls test for multiple comparisons.
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tion and not the IL-17-producing Th17 cells, it can 
be speculated that the failure of SalB to prevent T1D 
development in vivo is due to the fact that SalB showed 
no effect on the pathogenic Th17 population. There-
fore, in order to provide the most effective treatment of 
autoimmune/inflammatory disorders it might be more 
effective to use SalB in combination with some other 
substances that can downregulate the Th17 immune 
response. Since our previous research showed the an-
tidiabetic effect of the oregano extracts that contain 
SalB among other substances, possible candidates for 
synergistic studies could be found in the substances 
present in the oregano extracts.
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